Elevating R&D from Concept to Clarity
Strategic R&D Advisory | Cambridge, MA
Leva Scientific provides the strategic R&D guidance and data-driven insights needed to de-risk technology, accelerate development, and achieve critical milestones with confidence. Refine concepts, validate technology, and make informed decisions faster.
From Scientific Vision to Commercial Viability
Strategic Clarity
Develop a robust R&D roadmap that aligns with your corporate goals, IP strategy, and market landscape. I provide the executive-level perspective needed to make critical go/no-go decisions with confidence.
Technical Confidence
De-risk your core technology by identifying and solving critical challenges before they derail your timeline. Leverage my deep expertise to validate your platform's architecture and ensure its scientific and commercial feasibility.
Capital Efficiency
Achieve your milestones faster and with less wasted effort. I help you focus resources on what matters most, translating complex technical data into a clear narrative for investors, partners, and leadership.
How I Help: Areas of Advisory Focus
R&D Roadmap & IP Strategy: Aligning your technology development with long-term corporate goals, competitive landscape, and intellectual property strategy.
Technical Due Diligence: Providing deep technical assessment for venture capital, M&A, and strategic partnerships to validate technology and identify potential risks.
Platform De-risking & Validation: Designing and guiding key experiments to address critical scientific and engineering challenges, ensuring your core technology is robust and scalable.
Investor & Board Communication: Translating complex technical data into clear, compelling narratives that build confidence and secure funding.
Leva Scientific is a selective advisory practice built on a foundation of operational R&D leadership in the medtech and life sciences sectors, dedicated to deep, high-impact engagements.
About Me
Kyle C. Smith, PhD
For more than a decade, I've worked at the intersection of deep science and commercial strategy, helping innovative companies navigate the inherent uncertainty of R&D and turn breakthrough ideas into viable, market-ready technologies. Through my advisory work, I serve as a dedicated partner to leadership, providing the technical clarity and strategic foresight needed to make confident decisions. While I engage selectively in advisory projects, my career focus remains on operational R&D leadership — building and scaling ventures from concept to commercial launch.My expertise in medtech and life sciences — built on a foundation of research at MIT and MGH — was honed through leading projects from the lab bench to commercial scale. Whether it's architecting an IP portfolio, conducting technical due diligence for a critical acquisition, or validating a novel technology platform, I bring a hands-on, detail-oriented perspective to every challenge.My approach to R&D is rooted in de-risking novel platforms and building capital-efficient roadmaps — an operator-first methodology proven across both deep-tech hardware and scalable service models.
Proof of Performance
My expertise is built on a track record of translating complex technology into tangible business value. The following are representative examples of the results I deliver.
Secured $38M in Funding & Launched First Commercial Product
As a founding team member and R&D leader at MicroMedicine, I defined the technical strategy and R&D roadmap that served as the cornerstone for securing $38M in milestone-based venture funding. This leadership directly enabled the company to scale from a spin-out to a commercial-stage entity, culminating in the successful launch of the Sorterra™ cell processing platform.
Engineered a Capital-Efficient Business Pivot to Ensure Viability
As Co-Founder and CTO of BendBio, I have architected a critical strategic pivot in response to challenging VC market conditions. By shifting the company from a capital-intensive instrument model to a lean, high-margin consumables model, we have preserved 100% of founder equity, secured the company's first revenues, and achieved operational self-sufficiency without dilutive funding.
Created Foundational IP Anchoring a $35M Strategic Partnership
During my tenure at Massachusetts General Hospital, I served as a key inventor of a core microfluidics technology portfolio. This intellectual property was not only foundational for launching multiple spin-out ventures but also directly anchored a $35M strategic R&D partnership with Johnson & Johnson to develop next-generation diagnostic devices.